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Background Information 
Hypoplastic left heart syndrome (HLHS) is a rare congenital heart defect occurring in fewer 
than 0.5% of live births in the United States (Fruitman, 2000). It is characterized by a critically 
underdeveloped left ventricle with accompanying imperfections including septal defects, under-
sized aorta, and underdeveloped bicuspid and aortic semilunar valves (Mayo Clinic Staff, 2012; 
CDC, 2013). HLHS is detectable on ultrasound at the end of the first trimester of pregnancy 
allowing for early diagnosis and potential treatment in utero. While a protocol involving three 
surgeries exists to treat the condition, there is no cure for HLHS. Even with treatment, many 
patients eventually require a heart transplant due to congestive heart failure. 
 
Hypothesis and Rationale   
        We hypothesize that HLHS is caused by an up-regulation of hypoxia-inducible factor 1α 
(HIF1α) caused by prolonged hypoxia in the developing heart. Furthermore, we propose that a 
polymorphism in the endothelial nitric oxide synthase gene (eNOS) causes a decrease in basal levels 
of nitric oxide (NO), a potent vasodilator, in the blood stream and contributes to hypoxia. HIF1α 
expression, brought about by hypoxia and other environmental factors, regulates a number of 
transcription factors and genes vital to normal cardiogenesis. These factors combine to form a 
perfect storm in the developing heart, leading to the development of HLHS. 
When working properly, the eNOS enzyme promotes production and regulation of NO 
which dilates blood vessels and allows for proper blood flow throughout the body. eNOS is 
expressed in endothelial cells during early stages of cardiogenesis and naturally depletes starting as 
early as embryonic stage 14.5 (between days 33-36 of pregnancy) with only small traces remaining 
at birth (Bloch et al., 1999). Many researchers have identified that a polymorphism on exon 7 of the 
eNOS  gene, G894T, leads to a greater risk for congenital heart defects during early cardiogenesis 
(van Beynum et al., 2008; Bloch et al., 1999; Feng et al., 2002; Shaw, et al., 2005; Zhou et al., 
2014). The polymorphism corresponds to a down regulation of NO, leading to an inability to control 
blood pressure, cardiomyocyte apoptosis, and cell growth in cardiogenesis (Feng et al., 2002). 
Specifically, van Beynum et al. (2008) demonstrates a positive relationship between the G894T 
polymorphism and structural deformations of the heart. Feng et al. (2002) attributes the identified 
structural deformations to the increased and uncontrolled cardiomyocyte apoptosis found as a result 
of eNOS deficiency. Another result of the polymorphism is a decrease in available cyclic guanosine 
monophosphate (cGMP) (Bloch et al., 1999), which relates to the mechanism of vasodilation by NO 
(McQuillan, Leung, Marsden, Kostyk, & Kourembanas, 1994). Due to downregulation of NO, 
blood flow becomes restricted during cardiac development and prolonged hypoxia arises as a 
detriment to cardiogenesis. 
Hypoxia-inducible factor 1α (HIF1α) is a dimer of the heterodimeric transcription factor, 
HIF1 (Ziello, Jovin, and  Huang, 2007). According to Balligand, Feron, and Dessy, (2009) HIF1α is 
activated through various pathways, including hypoxia. HIF1α is hydroxylated in the combined 
presence of oxygen and prolyl hydroxylase (PHD), and is then degraded after binding to the von 
Hippel Lindau protein (pVHL). This process acts to regulate levels of HIF1α during periods of 
normal oxygenation. When confronted with conditions, such as hypoxia, that prevent HIF1α’s 
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hydroxylation, HIF1α is able to stabilize and complete the HIF1 complex after migrating to the cell 
nucleus. This contributes to increased levels of HIF1α during periods of low oxygenation 
(Balligand, Feron, and Dessy, 2009). While low oxygenation has been shown to increase levels of 
HIF1α, many other factors such as increased stress, NO levels, and inflammation have also been 
shown to increase levels of HIF1α (Gorlach, 2009). Chronic diseases, such as cardiovascular 
disease, diabetes, and autoimmune diseases as well as chronic environmental stress all contribute to 
higher levels of inflammatory proteins. If an epidemiological connection can be found among 
mothers of HLHS patients who have any of these diseases or environmental factors, increased 
HIF1α levels may be preliminarily implicated as the cause of HLHS. 
Gaber and colleagues (2013) studied left ventricle tissue samples from aborted, second 
trimester fetuses who were found to have HLHS and compared them to control samples obtained in 
a similar manner. HLHS samples were found to have higher nuclear expression of HIF1α. 
Furthermore, the phenomenon was mimicked in vitro using human pluripotent stem cells (hPSC’s). 
hPSC’s subjected to a hypoxic state during cardiac differentiation showed elevated HIF1α levels. 
The authors of the study indicate that this data points strongly to the assertion that hypoxia can 
reprogram the developing heart (Gaber, et al., 2013). This new data aligns with existing evidence 
that HIF1α plays an essential role in cardiac development by regulating key genes in ventricular 
formation (Compernolle et al., 2003). 
According to Krishnan et al, (2008) it has also been determined that HIF1α contributes to 
the regulation of NKX2.5, TBX5, and MEF2C. NKX2.5 and MEF2C are expressed very early on in 
the heart field of the developing embryo and continue to be expressed into the late stages of 
development. They are considered some of the earliest cardiac indicators (George, Colombo, 
Tergoff, 2014; Srivastava, Olson, 2000). NKX2.5 is also vital to the development of ventricular 
identity in the transition from the anterior-posterior patterning to the left-right patterning in the 
developed heart. Region specific knockouts of NKX2.5 exhibit elevated levels of Bmp10 which 
leads to hypertrophy of the developing ventricles (Gilbert, 2010). TBX5 is expressed exclusively in 
the left ventricle asymmetric to TBX20 in the right ventricle during heart patterning and ventricular 
septation. Together these genes are vital for normal ventricular septum formation and normal 
ventricular development (Gilbert, 2010).  
HIF1α is believed to regulate TBX5 and NKX2.5 by binding to Hypoxia Response Elements 
(HREs) contained within the promoters of the respective gene on the DNA. By binding to the 
promoter, the transcription of the gene is down regulated. (Krishnan et al., 2008). Experiments have 
shown that irregularly low doses of HIF1α result in the up-regulation of NKX2.5, TBX5, and 
MEF2C (Bohuslavova, et. al. 2013). Therefore, high doses of HIF1α likely result in the down 
regulation of these specific factors. The evidence-based roles of these downstream factors further 
implicate our proposed pathway connecting hypoxia and HIF1α to the development of HLHS. 
The full phenotypic scope of irregular expression of HIF1α and its regulation of downstream 
proteins and transcription factors is currently not well understood. There is, however, phenotypic 
evidence that, in tandem with our proposed pathway, points to the potential role of hypoxia and 
HIF1α in HLHS. Research has found that hearts afflicted with HLHS exhibit reduced levels of 
connexin 43 in intercalated discs (Mahtab, et. al, 2012), and that connexin 43 may be reduced under 
the same hypoxic conditions that promote HIF1α expression (Xianghong, et. al, 2013). 
Additionally, z-discs interact with titin and α-actinin to function properly, and both titin and α-
actinin have been exhibited in decreased levels when HIF1α levels are reduced (Krishnan). 
Therefore, it is possible that the inverse may be true, where increased levels of HIF1α lead to an 
overexpression of titan and α-actinin. Alpha-actinin is highly important in heart sarcomere function, 
and unusual expression may be linked to HLHS (Chiu, et. al, 2010; Wang, 2013). The importance 
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of these findings is not necessarily about how they function to create HLHS (as much information 
in that area has yet to be discovered). Rather, their importance lies in their ability to link HIF1α to 
the disease. 
 
Significance and Innovation 
A preliminary epidemiological study could provide a level of validity for our hypothesis. If 
mothers of HLHS patients tend to have inflammatory protein-causing diseases, our hypothesis 
connecting HIF1α to HLHS would be preliminarily supported. Additionally, we propose a series of 
simple laboratory tests. First, we propose the sequencing and analysis of HLHS patient samples for 
the eNOS polymorphism G894T. Next, we propose a simple ELISA assay to test for abnormal 
levels of HIF1α in cardiomyocytes derived from induced pluripotent stem cells (iPSCs) from HLHS 
patients. If a relevant correlation between the presence of a G894T and elevated levels of HIF1α 
exists, our pathway would be supported. In the future, it would be possible to perform both of these 
tests in utero, allowing for early diagnosis and potential prophylaxis. Tests may also be performed 
on the parents prior to pregnancy to screen for a predisposition to the G894T polymorphism or 
elevated HIF1α.  
In the event that early screenings using our proposed tests indicate a predisposition to 
HLHS, we hypothesize that it is possible to prevent the development of HLHS by attempting to 
treat the abnormal phenotype created by this polymorphism. This may be possible through the use 
of ACE inhibitors, statins or vasodilators, which have been proven to activate eNOS (Balligand, 
Feron, & Dessy, 2009). This would not only remedy the vasoconstriction caused by a lack of NO 
due to abnormal levels of eNOS, but it would also provide one mechanism to avoid the 
accumulation of HIF1α, preventing the abnormal downstream regulation of NKX2.5, TBX5, and 
MEF2C. 
Our hypothesis is significant because if supported it relies on a simple genetic test to 
determine if potential parents are at risk for passing on the polymorphisms to their offspring. If 
parents choose to have a child despite the risk there is the potential for treatment in utero that would 
remove the environmental conditions (hypoxia) that lead to the development of HLHS. The 
combination of genetic screening and in utero treatment could lead to the cure for HLHS ensuring 
no more children are born with this heart defect. Ultimately our proposed pathway is novel because 
it connects a polymorphism in eNOS to hypoxia, elevated HIF1α, various cardiac progenitors, and 
finally the development of HLHS.   
  
Summary 
The G894T polymorphism in eNOS during early stages of embryonic cardiogenesis results 
in a reduction of basal NO production, which results in vasoconstriction and prevention of HIF1α 
degradation. As a result, prolonged hypoxia in the developing heart brings about an accumulation of 
HIF1α. When combined with environmental factors such as inflammation and depleted levels of 
NO, the uncontrolled levels of HIF1α down regulate TBX5, NKX2.5, and MEF2C; genes 
responsible for development of the left ventricle. Compounded with data demonstrating that 
degradation of eNOS results in uncontrolled cardiomyocyte apoptosis, the greater expression of 
HIF1α results in an underdeveloped left ventricle corresponding to HLHS. Simple parental PCR 
testing for the G894T polymorphism in eNOS and ELISA assay for observing abnormal levels of 
HIF1α in iPSCs can result in an accurate diagnosis through our proposed mechanism of HLHS. A 
proposed treatment regimen calls for ACE inhibitors or statins to promote eNOS activation, leading 
to greater prevalence of NO, which eliminates one factor contributing to HIF1α abundance. 
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